Vir Biotechnology Inc (VIR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.71B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vir Biotechnology Inc (VIR) Earnings: Report Dates and Results
Vir Biotechnology (VIR) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Vir Biotechnology reported EPS of -$0.57, above the -$0.80 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VIR has an expected report date of Feb 22, 2027.
VIR Earnings Call
The latest VIR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 29 quarters below that had an estimate, VIR beat 12 and missed 17. The widest gap in the table came in the quarter ended Sep 30, 2021, when EPS landed 811.11% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.57 | -$0.80 | -$0.95 - -$0.58 | +28.75% | Beat | N/A | 6 | 2 up, 2 down | Nov 4, 2026 | N/A |
| Jun 30, 2026 | $0.47 | $0.83 | $0.47 - $0.83 | -43.37% | Miss | N/A | 4 | 0 up, 0 down | Aug 5, 2026 | $238.95M |
| Mar 31, 2026 | -$0.85 | $0.48 | -$0.59 - $1.06 | -277.08% | Miss | N/A | 4 | 1 up, 2 down | May 6, 2026 | N/A |
| Dec 31, 2025 | -$0.31 | -$0.54 | -$0.78 - -$0.16 | +42.59% | Beat | N/A | 7 | 2 up, 0 down | Feb 23, 2026 | $64.31M |
| Sep 30, 2025 | -$1.17 | -$0.70 | -$1.32 - -$0.60 | -67.14% | Miss | N/A | 7 | N/A | Nov 5, 2025 | $240000 |
| Jun 30, 2025 | -$0.80 | -$0.72 | -$0.88 - -$0.54 | -11.11% | Miss | N/A | 7 | 5 up, 1 down | Aug 6, 2025 | $1.21M |
| Mar 31, 2025 | -$0.88 | -$0.84 | -$1.03 - -$0.67 | -4.76% | Miss | N/A | 6 | 0 up, 1 down | May 7, 2025 | $3.03M |
| Dec 31, 2024 | -$0.76 | -$0.89 | -$0.96 - -$0.66 | +14.61% | Beat | N/A | 7 | 0 up, 0 down | Feb 26, 2025 | $12.37M |
| Sep 30, 2024 | -$1.56 | -$1.08 | -$1.75 - -$0.85 | -44.44% | Miss | N/A | 8 | 0 up, 0 down | Oct 31, 2024 | $2.38M |
| Jun 30, 2024 | -$1.02 | -$0.89 | -$1.10 - -$0.54 | -14.61% | Miss | N/A | 8 | 0 up, 0 down | Aug 1, 2024 | $3.08M |
| Mar 31, 2024 | -$0.48 | -$1.05 | -$1.32 - -$0.79 | +54.29% | Beat | N/A | 7 | 0 up, 0 down | May 2, 2024 | $56.38M |
| Dec 31, 2023 | -$0.86 | -$1.01 | -$1.26 - -$0.40 | +14.85% | Beat | N/A | 9 | 0 up, 0 down | Feb 22, 2024 | $16.79M |
| Sep 30, 2023 | -$1.22 | -$1.19 | -$1.49 - -$0.88 | -2.52% | Miss | -193.8% | 9 | 1 up, 0 down | Nov 2, 2023 | $2.64M |
| Jun 30, 2023 | -$1.45 | -$1.19 | -$1.55 - -$0.87 | -21.85% | Miss | N/A | 9 | 1 up, 0 down | Aug 3, 2023 | $3.80M |
| Mar 31, 2023 | -$1.06 | -$0.86 | -$1.15 - -$0.24 | -23.26% | Miss | -127.5% | 9 | 0 up, 0 down | May 4, 2023 | $62.96M |
| Dec 31, 2022 | -$0.76 | -$0.39 | -$1.20 - $0.84 | -94.87% | Miss | -119.4% | 8 | 1 up, 0 down | Feb 23, 2023 | $49.41M |
| Sep 30, 2022 | $1.30 | -$0.31 | -$1.19 - $1.78 | +519.35% | Beat | +58.5% | 10 | 0 up, 1 down | Nov 3, 2022 | $374.56M |
| Jun 30, 2022 | -$0.58 | $0.46 | -$0.53 - $0.99 | -226.09% | Miss | -226.1% | 8 | 1 up, 0 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | $3.85 | $3.62 | $1.52 - $5.37 | +6.35% | Beat | N/A | 7 | 1 up, 1 down | May 5, 2022 | $1.23B |
| Dec 31, 2021 | $3.92 | $3.04 | -$0.99 - $7.13 | +28.95% | Beat | N/A | 7 | 2 up, 0 down | Feb 24, 2022 | $812.75M |
| Sep 30, 2021 | $0.82 | $0.09 | -$0.73 - $2.55 | +811.11% | Beat | N/A | 7 | N/A | Nov 4, 2021 | $103.62M |
| Jun 30, 2021 | $0.46 | -$0.40 | -$0.95 - $0.92 | +215.00% | Beat | N/A | 7 | N/A | Aug 5, 2021 | $177.07M |
| Mar 31, 2021 | -$1.32 | -$0.11 | -$0.88 - $0.86 | N/A | N/A | N/A | 7 | N/A | May 6, 2021 | $1.98M |
| Dec 31, 2020 | -$0.83 | -$0.70 | -$0.76 - -$0.65 | -18.57% | Miss | N/A | 7 | N/A | Feb 25, 2021 | $1.73M |
| Sep 30, 2020 | -$0.67 | -$0.60 | -$0.77 - -$0.23 | -11.67% | Miss | N/A | 8 | N/A | Nov 10, 2020 | $1.93M |
| Jun 30, 2020 | -$0.27 | -$0.62 | -$0.72 - -$0.49 | +56.45% | Beat | N/A | 5 | N/A | Aug 11, 2020 | $66.99M |
| Mar 31, 2020 | -$0.71 | -$0.56 | -$0.60 - -$0.41 | -26.79% | Miss | N/A | 5 | N/A | May 12, 2020 | $5.72M |
| Dec 31, 2019 | -$0.69 | -$0.67 | -$0.81 - -$0.47 | -2.99% | Miss | N/A | 4 | N/A | Mar 26, 2020 | $980000 |
| Sep 30, 2019 | -$4.60 | -$3.33 | -$7.40 - -$0.62 | -38.14% | Miss | N/A | 4 | N/A | Oct 10, 2019 | $1.40M |
| Jun 30, 2019 | -$0.51 | -$0.71 | N/A | +28.17% | Beat | N/A | N/A | N/A | Sep 3, 2019 | $2.05M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.16, after -$3.82 the year before. It was -$5.80 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.16 | N/A |
| Dec 31, 2024 | -$3.82 | N/A |
| Dec 31, 2023 | -$4.59 | -220.5% |
| Dec 31, 2022 | $3.81 | -1.8% |
| Dec 31, 2021 | $3.88 | N/A |
| Dec 31, 2020 | -$2.48 | N/A |
| Dec 31, 2019 | -$5.80 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,300 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,314 | 12 | |
| 2026Q2 | Jun 30, 2026 | 5,662 | 13 | |
| 2026Q1 | Mar 31, 2026 | 5,646 | 12 | |
| 2025Q4 | Dec 31, 2025 | 8,301 | 16 | |
| 2025Q3 | Sep 30, 2025 | 4,533 | 13 | |
| 2025Q2 | Jun 30, 2025 | 6,715 | 15 | |
| 2025Q1 | Mar 31, 2025 | 6,396 | 13 | |
| 2024Q4 | Dec 31, 2024 | 6,988 | 13 |
2026Q3 Earnings Call
Opening remarks
Kiki Patel Head of Investor Relations Thank you, operator, and welcome, everyone. Earlier today, we issued a press release reporting our third quarter 2026 financial results and corporate update. Before we begin, I'd like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the therapeutic and commercial potential of our clinical and preclinical programs, our development plans and timelines, our collaborations with other companies, our cash runway and capital allocation priorities, and as otherwise described in the legal disclaimers accompanying our public presentations. These forward-looking statements involve substantial risks and uncertainties, which are described in our reports filed with the Securities and Exchange Commission, including our Forms 10-K, 10-Q, and 8-K, and could cause future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Joining me on today's call from Vir Biotechnology are Dr. Marianne De Backer, our President and Chief Executive Officer, and Aziz Sawaf, our Chief Financial Officer. The agenda for our call today is as follows: First, Marianne will provide a strategic update on where Vir Bio stands today, including an overview of our Phase III registrational program in hepatitis delta. Next, she will review the latest updates across the PRO-XTEN dual-masked T-cell engager program and present the highlights of our recently announced preclinical collaboration with Gilead. Next, Aziz will review the financial terms of our recent collaboration with Gilead and provide a summary of our third quarter 2026 financial results. And finally, Marianne will close the call, and we'll open the line for Q&A. With that, I'll now turn the call over to Marianne.
Marianne De Backer President and Chief Executive Officer Thank you, Kiki. Good afternoon, everyone, and thank you for joining us for Vir Biotechnology's Third Quarter 2026 Financial Results Conference Call. We are entering a pivotal period for Vir Bio, with the potential to transform hepatitis delta treatment while building a differentiated oncology franchise. Today, I will highlight significant progress across both those areas and why we believe Vir Bio is well positioned for meaningful value creation ahead. First, we've expanded our leadership team with the addition of Aziz Sawaf as Chief Financial Officer and Dr. David Liu as Chief Medical Officer. Both bring more than 20 years of experience in their respective fields, further bolstering our capabilities as we enter an important period for Vir Bio. With our leadership team strengthened, we are well positioned to execute against the significant opportunities and catalysts ahead. Second, our hepatitis delta program continues to advance through Phase III development.
Frequently Asked Questions About VIR
When is Vir Biotechnology's next earnings date?
Vir Biotechnology's next earnings report is expected for Feb 22, 2027.
Did VIR beat earnings estimates last quarter?
Yes. Vir Biotechnology reported EPS of -$0.57 for the quarter ended Sep 30, 2026, above the -$0.80 estimate, a 28.75% surprise.
What EPS do analysts expect from VIR next quarter?
The consensus EPS estimate for Vir Biotechnology for the quarter ending Dec 31, 2026 is -$0.53 from 10 analysts, with estimates from -$0.71 to -$0.10.
How often does VIR beat earnings estimates?
Vir Biotechnology beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -39.69%.
VIR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts